# Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

> **NCT02304185** · PHASE1 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** gp140, 50 mcg
- **BIOLOGICAL:** gp140, 50 mcg + Adjuvant
- **BIOLOGICAL:** gp140, 250 mcg
- **BIOLOGICAL:** gp140, 250 mcg + Adjuvant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02304185
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-06-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02304185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02304185, "Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02304185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*